Form 4: Avidity Biosciences Executive Sells Shares to Cover Tax Obligations After RSU Vesting

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, sold 11,151 shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Teresa McCarthy, Chief Human Resources Officer at Avidity Biosciences, sold 11,151 shares of common stock on December 18, 2024.
• The sale was executed at a weighted-average price of $32.66 per share, with individual transactions ranging from $32.66 to $32.66.
• This transaction was a 'sell-to-cover' to satisfy tax withholding obligations related to the vesting of 25,000 time-based restricted stock units (RSUs).
• The RSUs were initially granted as performance-based restricted stock units (PSUs) and converted to time-based RSUs on June 17, 2024, after a performance objective was met.
• The sale was not a discretionary trade by Ms. McCarthy but was mandated by the company's equity incentive plan.
• Ms. McCarthy has an instruction letter for the automatic sale of such 'sell-to-cover' shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It is not indicative of any positive or negative sentiment towards the company's performance or future prospects.

Industry Context

This is a routine transaction for executives who receive equity compensation. It is common for companies to require 'sell-to-cover' transactions to manage tax obligations for employees.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice in the industry for managing tax obligations related to equity compensation.
• Many companies, including those in the biotechnology sector like Avidity Biosciences, use restricted stock units (RSUs) as part of their compensation packages.
• The timing of the sale, immediately after vesting, is typical for these types of transactions.
• The price range of $32.66 to $32.66 is consistent with the market price of the stock at the time of the transaction.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but this is a routine transaction and not expected to have a significant effect on shareholders.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Avidity Biosciences, insider trading, Form 4, stock sale, restricted stock units, RSU, tax withholding, sell-to-cover, executive compensation